Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data
Maurizio Benucci,1 Arianna Damiani,2 Francesca Li Gobbi,1 Valentina Grossi,3 Maria Infantino,3 Mariangela Manfredi,3 Laura Niccoli,4 Fabrizio Cantini4 1Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 2Rheumatology Unit, University of Florence, Florence, I...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-04-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/therapeutic-potential-of-ixekizumab-in-the-treatment-of-ankylosing-spo-peer-reviewed-article-TCRM |
| _version_ | 1818718842283622400 |
|---|---|
| author | Benucci M Damiani A Li Gobbi F Grossi V Infantino M Manfredi M Niccoli L Cantini F |
| author_facet | Benucci M Damiani A Li Gobbi F Grossi V Infantino M Manfredi M Niccoli L Cantini F |
| author_sort | Benucci M |
| collection | DOAJ |
| description | Maurizio Benucci,1 Arianna Damiani,2 Francesca Li Gobbi,1 Valentina Grossi,3 Maria Infantino,3 Mariangela Manfredi,3 Laura Niccoli,4 Fabrizio Cantini4 1Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 2Rheumatology Unit, University of Florence, Florence, Italy; 3Immunology and Allergology Laboratory Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 4Rheumatology Unit, S. Stefano Hospital, Azienda USL-Toscana Centro, Prato, ItalyCorrespondence: Maurizio BenucciRheumatology Unit, Azienda Sanitaria USL-Toscana Centro, Hospital S. Giovanni di Dio, Via Torregalli 3, Florence 50143, ItalyTel +39-055-6932636Fax +39-055-6932099Email maurizio.benucci@uslcentro.toscana.itAbstract: Over the last 20 years, the greatly improved knowledges of underlying pathogenic mechanisms of AS, including the role of tumor necrosis factor (TNF), the interleukin 23/Th17 axis, and interleukin-17 (Il-17), constituted the rationale to develop biologics selectively inhibiting these pathways. For more than 10 years, anti-TNF biologics were successfully employed to treat AS, with marked improvement of signs and symptoms in around 60% of the patients. Recent knowledge of the pathophysiology of spondyloarthritis has highlighted the emerging role of the IL-17/IL-23 axis. New therapies with selective biological drugs have emerged in the treatment of this pathology. In this review, we evaluated the effects of ixekizumab, a new anti–IL-17A, that was licensed both by EMA and FDA in August 2019 for the treatment of ankylosing spondylitis. The review highlights the efficacy and safety data of the 3 randomized controlled trials (COAST V-COAST W-COAST X) and those of the extension to 52 weeks of COAST V and COAST W.Keywords: ixekizumab, ankylosing spondylitis, randomized control trials |
| first_indexed | 2024-12-17T19:57:28Z |
| format | Article |
| id | doaj.art-4f08e2754095488097299a6d5dd3953f |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-17T19:57:28Z |
| publishDate | 2020-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-4f08e2754095488097299a6d5dd3953f2022-12-21T21:34:33ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2020-04-01Volume 1628729753110Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical DataBenucci MDamiani ALi Gobbi FGrossi VInfantino MManfredi MNiccoli LCantini FMaurizio Benucci,1 Arianna Damiani,2 Francesca Li Gobbi,1 Valentina Grossi,3 Maria Infantino,3 Mariangela Manfredi,3 Laura Niccoli,4 Fabrizio Cantini4 1Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 2Rheumatology Unit, University of Florence, Florence, Italy; 3Immunology and Allergology Laboratory Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy; 4Rheumatology Unit, S. Stefano Hospital, Azienda USL-Toscana Centro, Prato, ItalyCorrespondence: Maurizio BenucciRheumatology Unit, Azienda Sanitaria USL-Toscana Centro, Hospital S. Giovanni di Dio, Via Torregalli 3, Florence 50143, ItalyTel +39-055-6932636Fax +39-055-6932099Email maurizio.benucci@uslcentro.toscana.itAbstract: Over the last 20 years, the greatly improved knowledges of underlying pathogenic mechanisms of AS, including the role of tumor necrosis factor (TNF), the interleukin 23/Th17 axis, and interleukin-17 (Il-17), constituted the rationale to develop biologics selectively inhibiting these pathways. For more than 10 years, anti-TNF biologics were successfully employed to treat AS, with marked improvement of signs and symptoms in around 60% of the patients. Recent knowledge of the pathophysiology of spondyloarthritis has highlighted the emerging role of the IL-17/IL-23 axis. New therapies with selective biological drugs have emerged in the treatment of this pathology. In this review, we evaluated the effects of ixekizumab, a new anti–IL-17A, that was licensed both by EMA and FDA in August 2019 for the treatment of ankylosing spondylitis. The review highlights the efficacy and safety data of the 3 randomized controlled trials (COAST V-COAST W-COAST X) and those of the extension to 52 weeks of COAST V and COAST W.Keywords: ixekizumab, ankylosing spondylitis, randomized control trialshttps://www.dovepress.com/therapeutic-potential-of-ixekizumab-in-the-treatment-of-ankylosing-spo-peer-reviewed-article-TCRMixekizumabankylosing spondylitisrandomized control trials |
| spellingShingle | Benucci M Damiani A Li Gobbi F Grossi V Infantino M Manfredi M Niccoli L Cantini F Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data Therapeutics and Clinical Risk Management ixekizumab ankylosing spondylitis randomized control trials |
| title | Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data |
| title_full | Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data |
| title_fullStr | Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data |
| title_full_unstemmed | Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data |
| title_short | Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data |
| title_sort | therapeutic potential of ixekizumab in the treatment of ankylosing spondylitis a review on the emerging clinical data |
| topic | ixekizumab ankylosing spondylitis randomized control trials |
| url | https://www.dovepress.com/therapeutic-potential-of-ixekizumab-in-the-treatment-of-ankylosing-spo-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT benuccim therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata AT damiania therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata AT ligobbif therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata AT grossiv therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata AT infantinom therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata AT manfredim therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata AT niccolil therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata AT cantinif therapeuticpotentialofixekizumabinthetreatmentofankylosingspondylitisareviewontheemergingclinicaldata |